92 related articles for article (PubMed ID: 3604471)
1. [Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rhode W
Z Urol Nephrol; 1987 Mar; 80(3):125-33. PubMed ID: 3604471
[TBL] [Abstract][Full Text] [Related]
2. [Conservative therapy of prostate cancer using Turisteron].
Schnorr D; Dörner G; Stahl F; Rohde W; Guddat HM
Z Urol Nephrol; 1987 Mar; 80(3):149-57. PubMed ID: 3111122
[TBL] [Abstract][Full Text] [Related]
3. [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
Z Urol Nephrol; 1987 Dec; 80(12):665-8. PubMed ID: 3126615
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
Stahl F; Schnorr D; Rohde W; Dörner G
Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron).
Dörner G; Schnorr D; Stahl F; Rohde W
Exp Clin Endocrinol; 1985 Dec; 86(2):190-6. PubMed ID: 3912197
[TBL] [Abstract][Full Text] [Related]
6. [Initial experience with ethinyl estradiol sulfonate (J 96) in the therapy of prostate carcinoma].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
Z Urol Nephrol; 1979 Mar; 72(3):153-7. PubMed ID: 380227
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of ethinyl estradiol sulfonate (Turisteron)--long-term results of a randomized compound study].
Böhm WD; Gorski J; Geissler W; Illig HD; Koch R
Z Urol Nephrol; 1987 Mar; 80(3):159-64. PubMed ID: 2440199
[TBL] [Abstract][Full Text] [Related]
8. Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.
Izumi K; Kadono Y; Shima T; Konaka H; Mizokami A; Koh E; Namiki M
Anticancer Res; 2010 Dec; 30(12):5201-5. PubMed ID: 21187513
[TBL] [Abstract][Full Text] [Related]
9. [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
Guddat HM; Schnorr D; Zemke F
Z Urol Nephrol; 1987 Mar; 80(3):165-70. PubMed ID: 3300098
[TBL] [Abstract][Full Text] [Related]
10. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
11. Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer.
Stahl F; Schnorr D; Bär CM; Fröhlich G; Dörner G
Exp Clin Endocrinol; 1989; 94(3):239-43. PubMed ID: 2630306
[TBL] [Abstract][Full Text] [Related]
12. [Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations].
Oettel M; Carol W; Gräser T; Klinger G; Mellinger U; Moore C; Schindler AE; Winkler UH
Zentralbl Gynakol; 1997; 119(12):597-606. PubMed ID: 9483810
[TBL] [Abstract][Full Text] [Related]
13. [Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].
Gorski J; Böhm WD; Illig HD; Koch R
Urologe A; 1988 Sep; 27(5):287-90. PubMed ID: 3051628
[TBL] [Abstract][Full Text] [Related]
14. [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications].
Drawz B; Hoffmann L; Drawz G; Russbüldt R
Z Urol Nephrol; 1987 Mar; 80(3):171-5. PubMed ID: 3604473
[TBL] [Abstract][Full Text] [Related]
15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
16. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
17. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
Pickles T; Agranovich A; Berthelet E; Duncan GG; Keyes M; Kwan W; McKenzie MR; Morris WJ;
Cancer; 2002 Jan; 94(2):362-7. PubMed ID: 11900222
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of advanced prostate cancer].
Langkopf B
Z Urol Nephrol; 1987 Mar; 80(3):121-4. PubMed ID: 3111121
[TBL] [Abstract][Full Text] [Related]
19. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
[TBL] [Abstract][Full Text] [Related]
20. Anemia in patients on combined androgen block therapy for prostate cancer.
Qian LX; Hua LX; Wu HF; Sui YG; Cheng SG; Zhang W; Li J; Wang XR
Asian J Androl; 2004 Dec; 6(4):383-4. PubMed ID: 15546035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
